ENLV - CIK 0001596812
The table below shows Enlivex Therapeutics Ltd.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2025 | Q1 2025 | Q2 2024 | Q1 2024 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $2.14M | - | $2.00M | - | $5.04M | - |
| SG&A | $937.00K |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| $987.00K |
| - |
| $1.61M |
| - |
| Operating income | -$3.08M | - | -$2.99M | - | -$6.65M | - |
| Income tax | - | - | - | - | - | - |
| Net income | -$1.87M | -$3.45M | -$3.10M | -$4.14M | -$6.79M | -$7.22M |
| EPS (diluted) | -$0.08 | - | -$0.16 | - | -$0.37 | - |